2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2852

Shared and Differing Risk Factors for PsA, Psoriasis, AS, and RA: A Series of Case-control Studies
Abstract Number: 2833

Shared Decision Making in Routine Clinical Practice: An Assessment of Audio-recorded Consultations with Rheumatoid Arthritis Patients
Abstract Number: 1830

Short- and Long-term Morbidity and Mortality Outcomes of African American Patients with Systemic Sclerosis-Related Interstitial Lung Disease
Abstract Number: 2358

Short-term Risk of Major Adverse Cardiovascular Events or Venous Thrombo-embolic Events in Patients with Rheumatoid Arthritis Initiating a Janus Kinase Inhibitor: A Meta-analysis of Randomised Controlled Trials
Abstract Number: 1558

Should Lupus Podocytopathy Be a Subclass in Class I and Class II Lupus Nephritis?
Abstract Number: 498

Should There Be Hierarchical Scoring Applied to Serologic Testing in the 2010 ACR/EULAR Classification Criteria?
Abstract Number: 1905

Sicca/Sjögren Syndrome Triggered by PD-1/PD-L1 Checkpoint Inhibitors: Data from the International ImmunoCancer Registry (ICIR)
Abstract Number: 2476

Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA
Abstract Number: 2734

Signaling Lymphocytic Activation Molecule Family (SLAMF) Receptors Deregulation Is Implicated in the Altered Function of NK Cells in Systemic Lupus Erythematosus
Abstract Number: 1629

Significance of Abnormal Nailfold Videocapillarscopy Among Patients with Raynaud’s Phenomenon And/or Suspected Connective Tissue Disease: A Cross-Sectional Single-Center US Experience
Abstract Number: 146

Simulated Rheumatology Clinic: Bridging Basic Science and Clinical Application
Abstract Number: 1784

Single Cell Analysis of Renal Myeloid Cells from NZB/WF1 Mice with Lupus Nephritis Reveals Multiple Subsets with Altered Functions
Abstract Number: 1011

Single Cell RNA Sequencing of Patients with Psoriatic Disease
Abstract Number: 2806

Single Cell RNA-sequencing Reveals Distinct Macrophage Subsets in the Joint with Differing Ontogenies During Steady-state and Arthritis
Abstract Number: 1022

Single Cell Transcriptome Analysis of Circulating Plasmacytoid Dendritic Cells and Switched Memory B-cells in SLE Patients Reveals Transcriptional Subsets Within the Classical Cell Lineages

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].